JPRN-jRCT2031220471招募中3 期
Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease - J1G-MC-LAKC
Masaki Takeshi0 个研究点目标入组 600 人开始时间: 2022年11月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 60age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Gradual and progressive change in cognitive function >=6 months prior to screening.
- •-A Mini-Mental (MMSE) score of 20 to 28 (inclusive) at screening.
- •-Has a P-tau result consistent with the presence of amyloid pathology.
- •-Has an amyloid PET scan result consistent with the presence of brain amyloid pathology.
- •-Have a reliable study partner who will provide written informed consent to participate and is in frequent contact with the participant.
- •-Have adequate literacy, vision, and hearing for the neuropsychological testing in the opinion of the investigator at the time of screening.
- •-Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
- •-Males and females will be eligible for this study.
- •-Women not of childbearing potential (WNOCBP) may participate in this trial.
排除标准
- •-Significant neurological disease affecting the central nervous system (CNS) other than AD, that may affect cognition or ability to complete the study.
- •-Current serious or unstable illnesses that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of <24 months.
- •-History of cancer with high risk of recurrence and preventing completion of the trial.
- •-Participants with any current primary psychiatric diagnosis other than AD that in the investigator's opinion, is likely to confound interpretation of the drug effect, affect cognitive assessment, or affect the participant's ability to complete the study.
- •-History of of clinically significant multiple or severe drug allergies.
- •-Have any clinically important abnormality at screening, as determined by investigator that could be detrimental to the participant, could compromise the study, or show evidence of other etiologies for dementia.
- •-Screening magnetic resonance imaging (MRI) which shows evidence of significant abnormality that would suggest another potential etiology for progressive dementia or a clinically significant finding that may impact the participant's ability to safely participate in the study.
- •-Have any contraindications for MRI or positron emission tomography (PET).
- •-Have had prior treatment with a passive anti-amyloid immunotherapy that is <5 half-lives prior to randomization.
- •-Have received active immunization against amyloid-beta peptide in any other study.
- •-Have known allergies to remternetug related compounds, or any components of the formulation.
研究者
相似试验
进行中（未招募）
1 期
Donanemab in Early Symptomatic Alzheimer’s DiseaseEUCTR2020-000077-25-PLEli Lilly and Company1,800
已完成
2 期
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT2080223944Eli Lilly Japan K.K.360
招募中
1 期
Donanemab in Early Symptomatic Alzheimer’s DiseaseEUCTR2020-000077-25-NLEli Lilly and Company1,736
已完成
3 期
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer*s DiseaseEarly Symptomatic Alzheimer's DiseaseAlzheimersenile psychosisNL-OMON52785Eli Lilly27
进行中（未招募）
2 期
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseAlzheimer DiseaseJPRN-jRCT2031210449Masaki Takeshi330